CN1665824A - 取代的芳基硼酸、它们的制备和它们的前体 - Google Patents
取代的芳基硼酸、它们的制备和它们的前体 Download PDFInfo
- Publication number
- CN1665824A CN1665824A CN038156237A CN03815623A CN1665824A CN 1665824 A CN1665824 A CN 1665824A CN 038156237 A CN038156237 A CN 038156237A CN 03815623 A CN03815623 A CN 03815623A CN 1665824 A CN1665824 A CN 1665824A
- Authority
- CN
- China
- Prior art keywords
- compound
- formula
- alkyl
- carbon
- definition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 239000002243 precursor Substances 0.000 title description 2
- 239000002253 acid Substances 0.000 title 1
- 125000003107 substituted aryl group Chemical group 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 44
- 238000000034 method Methods 0.000 claims abstract description 19
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 5
- 150000002148 esters Chemical class 0.000 claims abstract description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 34
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 32
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 24
- 125000003118 aryl group Chemical group 0.000 claims description 24
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 21
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 20
- -1 perfluoroalkyl sulfonate ester Chemical class 0.000 claims description 16
- 239000004327 boric acid Substances 0.000 claims description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 12
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 12
- 229910052794 bromium Inorganic materials 0.000 claims description 12
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 11
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 claims description 11
- 125000003545 alkoxy group Chemical group 0.000 claims description 9
- 229910052744 lithium Inorganic materials 0.000 claims description 9
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 8
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 8
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims description 8
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 claims description 8
- 229910052801 chlorine Inorganic materials 0.000 claims description 8
- 239000000460 chlorine Substances 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 7
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 7
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 7
- 229910052731 fluorine Inorganic materials 0.000 claims description 7
- 239000011737 fluorine Substances 0.000 claims description 7
- 229910052736 halogen Inorganic materials 0.000 claims description 7
- 150000002367 halogens Chemical class 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 150000003053 piperidines Chemical class 0.000 claims description 7
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 6
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical group [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 claims description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 6
- 239000002168 alkylating agent Substances 0.000 claims description 6
- 229940100198 alkylating agent Drugs 0.000 claims description 6
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 6
- 125000001246 bromo group Chemical group Br* 0.000 claims description 6
- CETVQRFGPOGIQJ-UHFFFAOYSA-N lithium;hexane Chemical compound [Li+].CCCCC[CH2-] CETVQRFGPOGIQJ-UHFFFAOYSA-N 0.000 claims description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 6
- 235000015320 potassium carbonate Nutrition 0.000 claims description 6
- WRECIMRULFAWHA-UHFFFAOYSA-N trimethyl borate Chemical group COB(OC)OC WRECIMRULFAWHA-UHFFFAOYSA-N 0.000 claims description 6
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 5
- 239000001257 hydrogen Substances 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 239000011630 iodine Chemical group 0.000 claims description 5
- 229910052740 iodine Chemical group 0.000 claims description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 5
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 4
- 125000006701 (C1-C7) alkyl group Chemical group 0.000 claims description 4
- 239000003513 alkali Substances 0.000 claims description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 125000004122 cyclic group Chemical group 0.000 claims description 4
- NNBZCPXTIHJBJL-UHFFFAOYSA-N decalin Chemical compound C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 claims description 4
- 125000000623 heterocyclic group Chemical group 0.000 claims description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 claims description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 4
- 239000001301 oxygen Substances 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical class [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 3
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 claims description 3
- 229910000024 caesium carbonate Inorganic materials 0.000 claims description 3
- UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical group [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 claims description 3
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 3
- 229920006395 saturated elastomer Polymers 0.000 claims description 3
- 235000017550 sodium carbonate Nutrition 0.000 claims description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 3
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 3
- AJSTXXYNEIHPMD-UHFFFAOYSA-N triethyl borate Chemical compound CCOB(OCC)OCC AJSTXXYNEIHPMD-UHFFFAOYSA-N 0.000 claims description 3
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 2
- 125000003282 alkyl amino group Chemical group 0.000 claims description 2
- 125000004429 atom Chemical group 0.000 claims description 2
- 150000001721 carbon Chemical group 0.000 claims description 2
- 239000012336 iodinating agent Substances 0.000 claims description 2
- 125000001624 naphthyl group Chemical group 0.000 claims description 2
- 238000000746 purification Methods 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 238000005885 boration reaction Methods 0.000 claims 1
- 230000002140 halogenating effect Effects 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 abstract description 6
- 108010021487 Nitric Oxide Synthase Proteins 0.000 abstract description 6
- 239000003112 inhibitor Substances 0.000 abstract description 3
- 241000124008 Mammalia Species 0.000 abstract 1
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 24
- 239000000243 solution Substances 0.000 description 12
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 description 6
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 5
- 230000031709 bromination Effects 0.000 description 5
- 238000005893 bromination reaction Methods 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 4
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 4
- LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Chemical compound IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- HHQJWDKIRXRTLS-UHFFFAOYSA-N n'-bromobutanediamide Chemical compound NC(=O)CCC(=O)NBr HHQJWDKIRXRTLS-UHFFFAOYSA-N 0.000 description 3
- 125000001979 organolithium group Chemical group 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- INKDAKMSOSCDGL-UHFFFAOYSA-N [O].OC1=CC=CC=C1 Chemical compound [O].OC1=CC=CC=C1 INKDAKMSOSCDGL-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
- 230000002152 alkylating effect Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 239000013067 intermediate product Substances 0.000 description 2
- ICIWUVCWSCSTAQ-UHFFFAOYSA-M iodate Chemical compound [O-]I(=O)=O ICIWUVCWSCSTAQ-UHFFFAOYSA-M 0.000 description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 150000004885 piperazines Chemical class 0.000 description 2
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- MFGOFGRYDNHJTA-UHFFFAOYSA-N 2-amino-1-(2-fluorophenyl)ethanol Chemical compound NCC(O)C1=CC=CC=C1F MFGOFGRYDNHJTA-UHFFFAOYSA-N 0.000 description 1
- LQLJZSJKRYTKTP-UHFFFAOYSA-N 2-dimethylaminoethyl chloride hydrochloride Chemical compound Cl.CN(C)CCCl LQLJZSJKRYTKTP-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 1
- 206010056370 Congestive cardiomyopathy Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 201000010046 Dilated cardiomyopathy Diseases 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 206010021138 Hypovolaemic shock Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 150000001499 aryl bromides Chemical class 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- HUCVOHYBFXVBRW-UHFFFAOYSA-M caesium hydroxide Inorganic materials [OH-].[Cs+] HUCVOHYBFXVBRW-UHFFFAOYSA-M 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000026781 habituation Effects 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000026045 iodination Effects 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 150000002642 lithium compounds Chemical class 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 150000002900 organolithium compounds Chemical class 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 235000007715 potassium iodide Nutrition 0.000 description 1
- 229960004839 potassium iodide Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 206010040560 shock Diseases 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C213/08—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions not involving the formation of amino groups, hydroxy groups or etherified or esterified hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
- C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
- C07C217/18—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
- C07C217/20—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by halogen atoms, by trihalomethyl, nitro or nitroso groups, or by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
本发明涉及式(V)的化合物及其硼酸烷基酯的制备方法,其中R1连接在苯环的2或3位,R2连接在5或6位,且R1、R2和G如本文定义。该化合物是制备用作哺乳动物的一氧化氮合成酶(NOS)抑制剂的2-氨基-6-(取代的-4-苯氧基)-取代的吡啶的关键合成中间产物。
Description
本发明涉及取代的芳基硼酸衍生物的一种新的制备途径,该衍生物是制备表现出作为一氧化氮合酶(NOS)抑制剂的活性的2-氨基-6-(2-取代的4-苯氧基)-取代的吡啶的有用中间产物。由取代的芳基硼酸衍生物制备的2-氨基-6-(2-取代的4-苯氧基)-取代的吡啶的实例公开在1998年8月13日出版的PCT国际申请出版物WO98/34919,此文献被全文引入本文以供参考。
在WO98/34919中被作为一氧化氮合酶(NOS)抑制剂公开的2-氨基-6-(2-取代的-4-苯氧基)-取代的吡啶可用于治疗哺乳动物的偏头痛炎症、中风、急性和慢性疼痛、血量减少性休克、外伤性中风、再灌注损伤、克罗恩氏病、溃疡性结肠炎、脓毒性休克、多发性硬化、与AIDS有关的痴呆、神经变性疾病、神经元毒性、阿耳茨海默氏病、化学物质依赖和成瘾、呕吐、癫痫、焦虑、精神病、头外伤、成人呼吸窘迫综合征(ARDS)、吗啡诱导的耐受和断瘾症状、炎性肠病、骨关节炎、类风湿性关节炎、排卵、扩张型心肌病、急性脊髓损伤、杭廷顿氏舞蹈病、帕金森病、青光眼、黄斑变性、糖尿病性神经病、糖尿病性肾病和癌症。
发明概述
本发明涉及下式的化合物的制备方法
该式V的化合物用作制备下式的2-氨基-6-(取代的-4-苯氧基)-取代的吡啶的合成中间产物:
其中在该式V的化合物中,R1取代基连接在芳基部分的碳2或3,而R2取代基连接在芳基部分的碳5或6;
各个R1和R2独立地选自H、(C1-C6)烷基、(C2-C6)链烯基、(C1-C6)烷氧基-(C1-C3)烷基、卤素、(C1-C6)烷氧基、(C1-C7)烷基、(C2-C10)烷氧基烷基以及具有第一碳和末端碳的-CH2(CH2)1-4CH2-基团,条件是该第一碳连接在芳基部分的碳2,而该末端碳连接在芳基部分的碳3,从而使环连接芳基部分的碳2和碳3,或者该第一碳连接在芳基部分的碳5,而该该末端碳连接在芳基部分的碳6,从而使环连接芳基部分的碳5和碳6;
G为氢、氨基羰基-(C1-C3)烷基-、氨基羰基-(C1-C3)烷基、二-[(C1-C3)烷基]-(C1-C3)烷基-和N(R3)(R4)(C1-C4)烷基,其中R3和R4独立地选自氢、(C1-C7)烷基、四氢萘和芳基烷基,其中该芳基烷基的芳基部分为苯基或萘基,而烷基部分为直链或支链,并包含1-6个碳原子,且其中该(C1-C7)烷基和该四氢萘和该芳基烷基的芳基部分可以任选被1-3个取代基,优选0-2个取代基取代,所述取代基独立地选自氟、氯、(C1-C4)烷氧基和(C1-C4)烷基氨基;
或者R3和R4与它们连接的氮一起形成哌嗪、哌啶、氮杂环丁烷或吡咯烷环或者包含6-14个环成员,其中1-3个为氮,0-2个为氧而剩余为碳的饱和或不饱和氮杂二环环状系统;
且其中该哌嗪、哌啶、氮杂环丁烷和吡咯烷环以及该氮杂二环环状系统可以任选被一个或多个取代基,优选0-2个取代基取代,所述取代基独立地选自(C1-C6)烷基、氨基、(C1-C6)烷基氨基、[二-(C1-C6)烷基]氨基、苯基取代的5-6元杂环,所述杂环包含1-4个环氮原子,且其中任何前述取代基的苯基部分可以任选被一个或多个,优选0-2个,独立地选自氟、氯、(C1-C3)烷基、(C1-C3)烷氧基、CF3和OCF3的取代基取代;
且其中该哌嗪、哌啶、氮杂环丁烷和吡咯烷环以及该氮杂二环环状系统可以在NR3R4环的氮原子或具有可利用的键合部位的该环的任何其它原子处与-(C0-C4)烷基-O-(其中该-(C0-C4)烷基-O-的氧为结构式V中所述的氧原子)连接;
或者G为式A的基团
其中Z为氮或CH,n为0或1,q为0、1、2或3,而p为0、1或2;
所述方法包括用碱处理式IV的化合物
其中R为(C1-C6)烷基,而R1、R2、G、R3和R4如以上定义,然后酸化形成所述式V的硼酸。
在该方法的另一个实施方案中,式IV、V或VI的化合物的该G部分是NR3R4(C1-C4)烷基,而NR3R4为哌啶、哌嗪、氮杂环丁烷或吡咯烷环或者下式的基团:
在该方法的另一方面,G为芳基,而基团GO-被氟替代。
在本发明的方法的另一方面,R、R1、R2、G、R3和R4如以上定义的式IV的化合物是通过用(1)C1-C10烷基锂和(2)硼酸C1-C6三烷基酯(C1-C6 trialkyl borate)处理下式的化合物制备的:
其中R1、R2、G、R3和R4如以上定义,而X选自溴或碘。
在制备式IV的化合物的该方法中,在一个优选的实施方案中,X为溴,并用(1)选自丁基锂、叔丁基锂、戊基锂或己基锂的有机锂试剂,优选己基锂和(2)选自硼酸三甲酯、硼酸三乙酯或硼酸三异丙酯的该硼酸三烷基酯,优选硼酸三甲酯,处理该式III的化合物。
在本发明的另一方面,R1、R2、G、R3和R4如以上定义的式III的化合物是通过用选自碘,N-碘代琥珀酰亚胺,溴和N-溴代琥珀酰亚胺的溴化或碘化剂,优选选自溴和N-溴代琥珀酰亚胺的溴化剂,最优选N-溴代琥珀酰亚胺处理下式的化合物制备的:
其中R1、R2、G、R3和R4如以上定义。
在本发明的另一方面,R1、R2、G、R3和R4如以上定义的式II的化合物是通过用烷基化剂GY,在碱性条件下,使用选自氢氧化钠、氢氧化钾、碳酸钠、碳酸氢钠、碳酸钾、碳酸氢钾或碳酸铯的碱,优选碳酸钾和氢氧化钾处理R1和R2如以上定义的下式的化合物来制备的:
在GY中,G如以上定义,而Y为被化合物I的酚氧替代的部分,该部分选择卤素、C1-C4全氟烷基磺酸酯、甲苯磺酸酯和甲磺酸酯,优选氯和溴。
除非另外指出,本文所用的术语“卤素”意指氟、氯、溴或碘。
除非另外指出,本文所用的术语“烷基”包括具有直链、支链或环部分或者它们的组合的饱和一价烃基。
除非另外指出,本文所用的术语“烷氧基”包括O-烷基基团,其中“烷基”如以上定义。
除非另外指出,本文所用的术语“芳基”包括由芳香烃通过除去一个氢而衍生得到的有机基团或连接了取代基的芳香碳环。
发明详述
在以下方案中例示了本发明的方法和本发明的化合物的制备。式II-V的化合物的制备如该方案和其后的讨论所述,其中除非另外指明,R、R1、R2、R3、R4、G、X、Y和Z如以上定义。
方案
总体上,该方案的合成顺序包括将化合物I的酚氧烷基化(步骤1)形成具有结构II的烷基化酚,将烷基化酚II溴化或碘化,优选溴化(步骤2)形成卤代芳基III,用有机锂试剂处理化合物III以用锂替代卤素X,其中X为溴或碘,并使中间产物芳基锂与硼酸烷基酯反应(步骤3)形成化合物IV,其中R为C1-C6烷基,并用碱水解形成硼酸盐,并由其通过酸化得到硼酸V(步骤4)。
在该方案的步骤1中,酚I的烷基化在溶剂如二乙醚、四氢呋喃、甘醇二甲醚或二甘醇二甲醚,优选四氢呋喃中以溶液形式完成。将酚I的溶液加到烷基化剂GY(其中G如以上定义,而Y为被以上定义的化合物I的酚氧替代的部分或官能团,优选氯、溴和碘)和碱(如氢氧化钠、氢氧化钾、碳酸钠、碳酸氢钠、碳酸钾、碳酸氢钾或碳酸铯,优选碳酸钾和氢氧化钾)的混合物中,然后加入第二溶剂如庚烷、己烷或甲苯,优选甲苯。将反应混合物在大约25℃至大约100℃下,优选在大约75℃下搅拌大约3小时至大约48小时,优选大约28小时以得到式II的化合物。
该方案的步骤2是芳基II的卤化。将在溶剂如甲醇、乙醇、丙醇、异丙醇,优选甲醇中的式II的化合物的溶液避光保护,并冷却至大约-10℃至大约10℃,优选大约0℃的温度,然后加入溴化钠或溴化钾以进行溴化,或者加入碘化钠或碘化钾以进行碘化,优选加入溴化钠以进行溴化。加入溴化试剂如溴或N-溴代琥珀酰胺,或者碘化试剂如碘或N-碘代琥珀酰亚胺,优选N-溴代琥珀酰胺,将所得的混合物于大约0℃至大约30℃下,优选大约25℃下搅拌大约30分钟至大约5小时,优选大约1小时的时间以得到式III的化合物。
该方案的步骤3是形成硼酸酯IV。将芳基溴III溶于质子惰性溶剂,优选醚类溶剂如二乙醚、四氢呋喃、甘醇二甲醚或二甘醇二甲醚,最优选四氢呋喃,并冷却至大约-30℃至大约-100℃的温度,优选大约-78℃,并用有机锂试剂如丁基锂、叔丁基锂、戊基锂或己基锂,优选己基锂处理大约15-大约120分钟,优选大约30分钟的时间,以形成有机锂化合物,其中锂与该方案的步骤2中引入的溴取代基交换。然后使如此形成的锂化合物与硼酸C1-C6三烷基酯,优选硼酸三甲酯、硼酸三乙酯或硼酸三异丙酯,最优选硼酸三甲酯反应,其中在大约0.5至大约6小时,优选大约3小时时间内加入该硼酸三烷基酯,同时保持温度为大约-30℃至大约-80℃,优选大约-78℃,以得到芳基硼酸酯IV,其中R为C1-C6烷基。
在该方案的步骤4中,通过用冷却的过量碱水解芳基硼酸酯IV,该碱选自氢氧化钠、氢氧化钾或氢氧化铯,优选氢氧化钠或氢氧化钾,以形成该芳基硼酸V的盐,然后调节pH至大约10.5至大约11.5,优选大约11,得到芳香硼酸V。
本发明由以下实施例举例说明,但它不受实施例细节的限制。
实施例1
[2-(2-乙基-5-甲氧基-苯氧基)-乙基]-二甲基-胺
往在四氢呋喃(490mL)中的3-乙基-5-甲氧基-苯酚(103.8g,682mmol)的溶液加入氢氧化钾(75.8g,887mmol)、碳酸钾(235.7g,1.71mol,粉末形式)和1-氯-2-二甲基氨基-乙烷盐酸盐(98.2g,682mmol),然后加入甲苯(1.10L)。将混合物在75℃下搅拌28小时。将反应混合物倾入冰水(1.0L)。用水(1.0L)洗涤有机层,然后用1L的1M HCl洗涤两次。将饱和碳酸氢钠水溶液(1.2L)加到合并的水提取物中,用30%氢氧化钠溶液(220mL)调节pH至11。用2个0.8L部分的叔丁基甲基醚从水相中萃取产物。将合并的有机萃取物浓缩,得到144.2g(91%产率)的[2-(2-乙基-5-甲氧基-苯氧基)-乙基]-二甲基-胺,为一种黄色油。
1H NMR(CDCl3,400MHz):δ=1.16(t,J=7.5Hz,3H),2.36(s,6H),2.57(q,J=7.5Hz,2H),2.77(t,J=6.0Hz,2H),3.78(s,3H),4.06(t,J=6.0Hz,2H),6.41-6.44(m,2H),7.04(m,1H).
实施例2
[2-(4-溴代-2-乙基-5-甲氧基-苯氧基)-乙基]-二甲基-胺
将在甲醇(1.3L)中的[2-(2-乙基-5-甲氧基-苯氧基)-乙基]-二甲基-胺(143.6g,0.64mol)的溶液进行避光保护。往在冰浴中冷却的该溶液加入溴化钠(66.2g,0.64mol),然后滴加N-溴代琥珀酰胺(114.5g,0.64mol)以保持温度在20℃。将此澄清的黄色溶液于室温下搅拌1小时,然后倾入10%硫代硫酸钠溶液(1.5L)中,并最终用1个1L部分和2个0.5L部分的叔丁基甲基醚萃取。用0.5L的水将合并的有机萃取物洗涤两次,然后浓缩得到184.0g(94%产率)的[2-(4-溴代-2-乙基-5-甲氧基-苯氧基)-乙基]-二甲基-胺,为一种橙色油。
1H NMR(CDCl3,400MHz):δ=1.15(t,J=7.5Hz,3H)2.36(s,6H),2.55(dq,J=7.5Hz,J=0.5Hz,2H),2.76(t,J=6.0Hz,2H),3.87(s,3H),4.07(t,J=6.0Hz,2H),6.47(s,1H),7.26(t,J=0.5Hz,1H).
实施例3
[4-(2-二甲基氨基-乙氧基)-5-乙基-2-甲氧基]-苯基-硼酸
在惰性气氛下,将[2-(4-溴代-2-乙基-5-甲氧基-苯氧基)-乙基]-二甲基-胺(179.8g,595mmol)溶于四氢呋喃(0.86L)。将反应混合物冷却至-78℃,然后在3小时内加入在己烷中的2.5M己基锂溶液(250mL,625mmol),同时保持温度处在或低于-75℃。将该混合物搅拌30分钟。在3小时内加入硼酸三甲酯(99.5mL,892mmol),并保持温度在-75℃至-78℃。5分钟后,移出冷却浴,并使混合物温热至-50℃(30分钟)然后倾入冷却的1M氢氧化钠溶液(2.0L)。用2个0.5L部分的叔丁基甲基醚萃取所得的混合物。将饱和碳酸氢钠溶液(0.5L)加到水层,并用32%盐酸(165mL)调节pH至11。用2个2.0L部分和1个0.2L部分的叔丁基甲基醚萃取沉淀的产物。合并有机萃取物,并浓缩得到127.3g(81%产率)的[4-(2-二甲基氨基-乙氧基)-5-乙基-2甲氧基]-苯基-硼酸,为一种黄色固体,m.p.99℃(在102℃下分解)。
1H NMR(CDCl3,400MHz):δ=1.16(t,J=7.5Hz,3H),2.39(s,6H),2.58(q,J=7.5Hz,2H),2.82(t,J=5.9Hz,2H),3.89(s,3H),4.15(t,J=5.9,2H),6.27(bs,2H),6.43(s,1H),7.57(s,1H).
Claims (15)
1.下式的化合物的制备方法:
其中在该式V的化合物中,R1取代基连接在芳基部分的碳2或3,而R2取代基连接在芳基部分的碳5或6;
各个R1和R2独立地选自H、(C1-C6)烷基、(C2-C6)链烯基、(C1-C6)烷氧基-(C1-C3)烷基、氟、氯、(C1-C6)烷氧基、(C1-C7)烷基和(C2-C10)烷氧基烷基,以及具有第一碳和末端碳的-CH2(CH2)1-4CH2-,条件是该第一碳连接至芳基部分的碳2,而该末端碳连接至芳基部分的碳3,从而使环连接芳基部分的碳2和碳3,或者该第一碳连接至芳基部分的碳5,而该该末端碳连接至芳基部分的碳6,从而使环连接芳基部分的碳5和碳6;
G为氢、氨基羰基-(C1-C3)烷基-、氨基羰基-(C1-C3)烷基、二-[(C1-C3)烷基]-(C1-C3)烷基-和N(R3)(R4)(C1-C4)烷基,其中R3和R4独立地选自氢、(C1-C7)烷基、四氢萘和芳基烷基,其中该芳基烷基的芳基部分为苯基或萘基,而烷基部分为直链或支链,并包含1-6个碳原子,且其中该(C1-C7)烷基和该四氢萘和该芳基烷基的芳基部分可以任选被1-3个取代基,优选0-2个取代基取代,所述取代基独立地选自氟、氯、氨基、(C1-C4)烷氧基和(C1-C4)烷基氨基;
或者R3和R4与它们连接的氮一起形成哌嗪、哌啶、氮杂环丁烷或吡咯烷环或者包含6-14个环成员,其中1-3个为氮,0-2个为氧而剩余为碳的饱和或不饱和氮杂二环环状系统;
且其中所述哌嗪、哌啶、氮杂环丁烷和吡咯烷环以及所述氮杂二环环状系统可以任选被一个或多个取代基,优选0-2个取代基取代,所述取代基独立地选自(C1-C6)烷基、氨基、(C1-C6)烷基氨基、[二-(C1-C6)烷基]氨基、苯基取代的5-6元杂环,所述杂环包含1-4个环氮原子,且其中任何前述取代基的苯基部分可以任选被一个或多个,优选0-2个,独立地选自氟、氯、(C1-C3)烷基、(C1-C3)烷氧基、CF3和OCF3的取代基取代;
且其中所述哌嗪、哌啶、氮杂环丁烷和吡咯烷环以及所述氮杂二环环状系统可以在NR3R4环的氮原子或具有可利用的键合部位的该环的任何其它原子处与-(C0-C4)烷基-O-(其中该-(C0-C4)烷基-O-的氧为结构式V中所述的氧原子)连接;
或者G为式A的基团
其中Z为氮或CH,n为0或1,q为0、1、2或3,而p为0、1或2;
所述方法包括(1)用碱处理下式的化合物
其中R为(C1-C6)烷基,而R1、R2、G、R3和R4如以上定义,和(2)酸化以形成所述式V的硼酸。
5.权利要求1的方法,其中式IV的化合物的R、R1和R2和式V的化合物的R1和R2如权利要求1中定义,且其中在式IV的化合物和式V的化合物中,G为NR3R4(C1-C4)烷基,而NR3R4为哌啶、哌嗪、氮杂环丁烷或吡咯烷。
6.权利要求2的方法,其中在式III的化合物中,G为NR3R4(C1-C4)烷基,而NR3R4为哌啶、哌嗪、氮杂环丁烷或吡咯烷。
7.权利要求3的方法,其中在式II的化合物中,R1和R2如权利要求3中定义,G为NR3R4(C1-C4)烷基,而NR3R4为哌啶、哌嗪、氮杂环丁烷或吡咯烷。
8.权利要求4的方法,其中式II的化合物通过用烷基化剂GY在碱性条件下处理式I的化合物来制备,在式GY中G为NR3R4(C1-C4)烷基,NR3R4为哌啶、哌嗪、氮杂环丁烷或吡咯烷,而Y为选自卤素、C1-C4全氟烷基磺酸酯、甲苯磺酸酯和甲磺酸酯的部分。
9.权利要求3的方法,其中G和NR3R4如权利要求9中定义的式II的化合物是用烷基化剂GY在碱性条件下处理式I的化合物来制备的,其中G和NR3R4如权利要求9中定义,而Y为选自卤素、C1-C4全氟烷基磺酸酯、甲苯磺酸酯和甲磺酸酯。
10.权利要求2的方法,其中式IV的化合物是通过用选自丁基锂、叔丁基锂、戊基锂或己基锂的烷基锂处理X为溴的式III的化合物来制备的,所述硼酸化剂选自硼酸三甲酯、硼酸三乙酯或硼酸三异丙酯。
11.权利要求3的方法,其中式III的化合物是通过用选自溴和N-溴代琥珀酰亚胺的卤化剂处理式II的化合物来制备的。
12.权利要求4的方法,其中式II的化合物是通过用烷基化剂GY在选自以下组的碱存在下处理式I的化合物来制备的:氢氧化钠、氢氧化钾、碳酸钠、碳酸氢钠、碳酸钾、碳酸氢钾、碳酸铯及其混合物。
13.下式的化合物
或其盐,其中R1、R2、G、R3和R4如权利要求1中定义。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39350102P | 2002-07-03 | 2002-07-03 | |
US60/393,501 | 2002-07-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1665824A true CN1665824A (zh) | 2005-09-07 |
Family
ID=30115592
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN038156237A Pending CN1665824A (zh) | 2002-07-03 | 2003-06-23 | 取代的芳基硼酸、它们的制备和它们的前体 |
Country Status (12)
Country | Link |
---|---|
US (1) | US7045652B2 (zh) |
EP (1) | EP1519940A1 (zh) |
JP (1) | JP2005531642A (zh) |
CN (1) | CN1665824A (zh) |
AU (1) | AU2003244968A1 (zh) |
BR (1) | BR0312335A (zh) |
CA (1) | CA2491029A1 (zh) |
IL (1) | IL165826A0 (zh) |
MX (1) | MXPA05000258A (zh) |
RU (1) | RU2004139087A (zh) |
WO (1) | WO2004005301A1 (zh) |
ZA (1) | ZA200410195B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104144933A (zh) * | 2012-08-06 | 2014-11-12 | 意大利合成制造有限公司 | 制备2-氰基苯基硼酸和其酯的方法 |
CN108409767A (zh) * | 2018-04-13 | 2018-08-17 | 上海泰坦科技股份有限公司 | 一种杂环联苯硼酸的制备方法 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6858592B2 (en) * | 2001-06-29 | 2005-02-22 | Genzyme Corporation | Aryl boronic acids for treating obesity |
US7041280B2 (en) * | 2001-06-29 | 2006-05-09 | Genzyme Corporation | Aryl boronate functionalized polymers for treating obesity |
US7145040B2 (en) * | 2004-07-02 | 2006-12-05 | Bristol-Myers Squibb Co. | Process for the preparation of amino acids useful in the preparation of peptide receptor modulators |
JO3598B1 (ar) * | 2006-10-10 | 2020-07-05 | Infinity Discovery Inc | الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني |
JP2013518886A (ja) * | 2010-02-03 | 2013-05-23 | インフイニトイ プハルマセウトイカルス インコーポレイテッド | 脂肪酸アミドヒドロラーゼ阻害剤 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1064252A (en) | 1963-09-19 | 1967-04-05 | Ici Ltd | Amides and pharmaceutical compositions containing them |
GB1177548A (en) | 1967-11-28 | 1970-01-14 | Ici Ltd | Phenoxy-and Anilino-Alkanoic Acid Amides |
CA2091864C (en) * | 1992-03-26 | 1999-09-07 | Tomokazu Hino | Process for producing halogenophenoxyfatty acid derivatives by selective halogenation and halogenophenoxyfatty acid derivatives |
US5550134A (en) | 1995-05-10 | 1996-08-27 | Eli Lilly And Company | Methods for inhibiting bone loss |
CN1523015A (zh) | 1997-02-10 | 2004-08-25 | �Ʒ� | 2-氨基-6-(2-取代的-4-苯氧基)取代的吡啶类化合物 |
US6235771B1 (en) | 1998-12-21 | 2001-05-22 | Takeda Chemical Industries, Ltd. | Anilide derivative, production and use thereof |
UA72611C2 (uk) * | 2000-05-17 | 2005-03-15 | Орто-Макнейл Фармацевтикал, Інк. | Похідні заміщеного піролопіридинону, корисні як інгібітори фосфодіестерази |
-
2003
- 2003-06-03 US US10/453,433 patent/US7045652B2/en not_active Expired - Fee Related
- 2003-06-23 RU RU2004139087/04A patent/RU2004139087A/ru not_active Application Discontinuation
- 2003-06-23 CA CA002491029A patent/CA2491029A1/en not_active Abandoned
- 2003-06-23 AU AU2003244968A patent/AU2003244968A1/en not_active Abandoned
- 2003-06-23 CN CN038156237A patent/CN1665824A/zh active Pending
- 2003-06-23 JP JP2004519102A patent/JP2005531642A/ja not_active Withdrawn
- 2003-06-23 BR BR0312335-9A patent/BR0312335A/pt not_active IP Right Cessation
- 2003-06-23 EP EP03738442A patent/EP1519940A1/en not_active Withdrawn
- 2003-06-23 IL IL16582603A patent/IL165826A0/xx unknown
- 2003-06-23 MX MXPA05000258A patent/MXPA05000258A/es unknown
- 2003-06-23 WO PCT/IB2003/002947 patent/WO2004005301A1/en not_active Application Discontinuation
-
2004
- 2004-12-17 ZA ZA200410195A patent/ZA200410195B/en unknown
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104144933A (zh) * | 2012-08-06 | 2014-11-12 | 意大利合成制造有限公司 | 制备2-氰基苯基硼酸和其酯的方法 |
CN108409767A (zh) * | 2018-04-13 | 2018-08-17 | 上海泰坦科技股份有限公司 | 一种杂环联苯硼酸的制备方法 |
CN108409767B (zh) * | 2018-04-13 | 2020-07-10 | 上海泰坦科技股份有限公司 | 一种杂环联苯硼酸的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CA2491029A1 (en) | 2004-01-15 |
BR0312335A (pt) | 2005-04-12 |
US20040038940A1 (en) | 2004-02-26 |
EP1519940A1 (en) | 2005-04-06 |
US7045652B2 (en) | 2006-05-16 |
IL165826A0 (en) | 2006-01-15 |
AU2003244968A1 (en) | 2004-01-23 |
JP2005531642A (ja) | 2005-10-20 |
MXPA05000258A (es) | 2005-04-11 |
ZA200410195B (en) | 2006-07-26 |
WO2004005301A1 (en) | 2004-01-15 |
RU2004139087A (ru) | 2005-07-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9469649B2 (en) | Synthetic voacangine | |
US9187419B2 (en) | Intermediates of sitagliptin and preparation process thereof | |
CN1880221A (zh) | 一种制备十二氢十二硼酸盐的方法 | |
CN1665824A (zh) | 取代的芳基硼酸、它们的制备和它们的前体 | |
CN1571767A (zh) | 托特罗定的制备方法 | |
WO2014097306A1 (en) | Stable and pure polymorphic form of bortezomib | |
EP2032522B1 (en) | Shortened synthesis using paraformaldehyde or trioxane | |
CN1104409C (zh) | 氨基四氢萘酮衍生物及其制备方法 | |
JPH0794450B2 (ja) | 置換1,3−ジオキソラン−2−オン誘導体の製法 | |
JP2001039979A (ja) | オクタヒドロピロロ[3,4−b]ピリジンの製造方法 | |
CN101077872A (zh) | 依托度酸甲酯的制备方法 | |
US9573896B2 (en) | Methods for preparing d-threo-methylphenidate using diazomethane, and compositions thereof | |
CN1910180B (zh) | 制备2-(乙氧基甲基)-托烷衍生物的方法 | |
KR20050016756A (ko) | 치환된 아릴 보론산, 그의 제조 방법 및 그의 전구체 | |
JP3941338B2 (ja) | 6−ヒドロキシ−2−ナフチルカルビノール及びその製造方法 | |
KR101113791B1 (ko) | 신규한 포타슘 아지도아릴트리플루오로보레이트 유도체 및 그 제조방법 | |
US8093391B2 (en) | Process for the preparation of substantially pure palonosetron and its acid salts | |
KR101491007B1 (ko) | 에제티밉 중간체의 제조방법 | |
RU2135446C1 (ru) | Способ получения 1-(н-пропил)-2-гидро[60]-фуллеренов | |
US20100261905A1 (en) | Ruthenium Catalysts for the Production of Hydrocodone, Hydromorphone or a Derivative Thereof | |
CN101646680B (zh) | 制备6-羟乙基青霉烷化合物的方法 | |
JP2011526257A (ja) | N−フェニル−n−(4−ピペリジニル)アミド塩の製造方法 | |
CA2433516A1 (en) | Processes for preparing chromanylbenzoic acids | |
US20030158428A1 (en) | Intermediates and processes for preparing substituted chromanol derivatives | |
CN1569828A (zh) | 2-n,n-二甲氨基-1,3-丙二黄原酸酯及其合成方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1076818 Country of ref document: HK |
|
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1076818 Country of ref document: HK |